#Ireland #Galway #InVera Medical #Infusion Device #Chronic Venous Disease

InVera Medical's Breakthrough Infusion Device

InVera Medical, an Irish medical device innovator dedicated to advancing minimally invasive technologies, recently announced the FDA's 510(k) clearance for its latest product: the InVera Infusion Device. This groundbreaking device is set to transform the approach to treating Chronic Venous Disease (CVD), which affects a staggering one in four adults. This progressive condition can escalate from visible varicose veins to painful leg ulcers if left untreated, highlighting a critical need for effective interventions.

CVD impacts over 120 million individuals in the US and Europe, yet a mere 1% of those suffering receive annual treatment. This stark statistic underscores the urgent demand for improved therapeutic options, a gap that InVera Medical aims to bridge through their innovative infusion technology.

What Makes the InVera Infusion Device Unique?

The InVera Infusion Device represents a significant advancement in the treatment of diseased leg veins, offering a non-thermal catheter specifically designed for enhanced sclerosant infusion. By mechanically preparing the vein wall, the device facilitates the effective delivery of treatment deeper into the layers of the vein. This approach is a departure from traditional thermal technologies that often require patients to endure multiple painful injections for anesthesia and can lead to complications such as nerve injuries, bruising, and prolonged recovery times.

The unique design of the 5Fr catheter, featuring a novel helical coil, disrupts the inner media layer of the vein, ensuring a more efficient infusion process. As a result, this minimally invasive procedure significantly reduces the need for multiple injections, providing a more comfortable experience for the patient and expediting recovery times. Unlike conventional methods that may necessitate repeat procedures or involve permanent glue implantation, the InVera Infusion Device positions itself as a safer, more effective, and less invasive alternative for patients struggling with CVD.

Clinical Need and Market Implications

According to Dr. Nigel Phelan, Chief Medical Officer and Co-Founder of InVera Medical, the market is in dire need of non-thermal solutions that deliver both safety and effectiveness for CVD treatment. Often, existing procedures involve significant discomfort for patients, leaving them susceptible to complications that hinder their recovery and overall experience. The InVera Infusion Device aims to improve this narrative by addressing the inherent limitations of both thermal and non-thermal methods currently in practice.

The successful clearance from the FDA and the CE Mark approval are monumental achievements for InVera Medical, opening doors for a limited market launch in selected centers across the US and Europe this year. With promising 12-month pilot study data showing strong safety and procedural outcomes, the company expresses enthusiasm about offering patients and healthcare providers a viable option that could potentially benefit millions.

Looking Ahead

Founded in 2018, InVera Medical continues to focus on developing catheter-based solutions for various vein disease conditions through a patient-centric, scientifically-informed lens. The launch of the InVera Infusion Device is not merely an introduction of another product; it reflects an ongoing commitment to enhancing patient care within the field of venous disease treatment. As the fastest-growing segment in the market, the non-thermal procedures for superficial venous reflux are seeing more than 1 million annual interventions in the US alone, positioning InVera Medical at the forefront of this rapidly expanding industry.

In conclusion, the advent of the InVera Infusion Device promises to revolutionize the management of Chronic Venous Disease, offering patients a more humane and effective treatment pathway. With advances like these, InVera Medical is not just changing the game; it’s paving the road towards a future where CVD treatment is both accessible and efficient for everyone in need.